CCCardiol CroatCardiologia CroaticaCardiol. Croat.1848-543X1848-5448Croatian Cardiac SocietyCC_11(10-11)_43910.15836/ccar2016.439Extended AbstractResults of introduction of ticagrelor in acute ST-segment elevation myocardial infarction in treatment in Croatiahttp://orcid.org/0000-0002-7060-8375BabićZdravko1http://orcid.org/0000-0002-1482-6503BulumJoško2http://orcid.org/0000-0001-7394-6698BrusichSandro3http://orcid.org/0000-0002-9882-9145PintarićHrvoje1SteinerRobert4KristićIvica5http://orcid.org/0000-0002-4462-8647VuksanovićIlko6ŠtambukKrešimir7http://orcid.org/0000-0003-4488-0559ŠikićJozica8ZekanovićDražen9PrvulovićĐeiti10KozmarDamir11http://orcid.org/0000-0001-9101-1570MiličićDavor2University Hospital Center «Sestre milosrdnice», Zagreb, CroatiaUniversity Hospital Center Zagreb, Zagreb, CroatiaUniversity Hospital Center Rijeka, Rijeka, CroatiaUniversity Hospital Center Osijek, Osijek, CroatiaUniversity Hospital Center Split, Split, CroatiaUniversity Hospital Dubrava, Zagreb, CroatiaClinic for Cardiovascular Diseases Magdalena, Krapinske Toplice, CroatiaUniversity Hospital «Sveti Duh», Zagreb, CroatiaZadar General Hospital, Zadar, CroatiaGeneral Hospital «Dr. Josip Benčević», Slavonski Brod, CroatiaClinical Hospital «Merkur», Zagreb, CroatiaAddress for correspondence: Zdravko Babić, Klinički bolnički centar Sestre milosrdnice, Vinogradska 29, HR-10000 Zagreb, Croatia. / Phone: +385-1-3787-937 / E-mail: zbabic@net.hr1120161110-1143943903102016101020162016Croatian Cardiac SocietyKeywords: acute ST segment elevation myocardial infarctionticagrelorclopidogrel
Introduction: PLATO (“Platelet Inhibition and Patient Outcomes”) study demonstrated advantage of ticagrelor in comparison with clopidogrel in acute coronary syndrome in prevention of the cardiovascular death, myocardial infarction and stroke. These results introduced ticagrelor in the European Society of Cardiology and other guidelines for management of acute coronary syndrome. (1-3)
Patients and Methods: This prospective multicentric observational study compares results of clopidogrel and ticagrelor in the treatment of acute ST-elevation myocardial infarction (STEMI) on national level. Authors investigated acute STEMI patients treated with primary percutaneous coronary intervention (pPCI) in 11 Croatian pPCI centers between June 1st 2015 and May 31st 2016. Patients were divided in three groups: the ticagrelor group, converted group (treatment initiated with clopidogrel and replaced with ticagrelor), and clopidogrel group.
Results: In 1947 investigated acute STEMI patients treated with pPCI investigators revealed statistically significant better results of treatment (postprocedural TIMI 3 flow, intrahospital mortality) with statistically significant less clinicaly significant bleeding in those treated with ticagrelor in comparision with those treated only with clopidogrel.
Conclusion: These findings may be considered as real-life confirmation of similar results obtained in randomized studies.
LiteratureStegPGJamesSHarringtonRAArdissinoDBeckerRCCannonCPPLATO Study Group. Circulation. 2010;122(21):2131–41. 10.1161/CIRCULATIONAHA.109.92758221060072Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-619. DOI: http://dx.doi.org/10.1093/eurheartj/ehs215WallentinLBeckerRCBudajACannonCPEmanuelssonHHeldCPLATO Investigators. Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med. 2009;361(11):1045–57. 10.1056/NEJMoa090432719717846